Cargando…

Chemotherapy and quality of life in advanced NSCLC – reply

Detalles Bibliográficos
Autores principales:	Anderson, Heather, Carmichael, Jim, Nicolson, Marianne, Hopwood, Penny, Thatcher, Nick
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2001
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363918/ http://dx.doi.org/10.1054/bjoc.2001.1852

Ejemplares similares

Chemotherapy and quality of life in advanced NSCLC
por: Farrugia, D, et al.
Publicado: (2001)

Reply: Internet chemotherapy information is of good quality: assessment with the DISCERN tool
por: Davies, E, et al.
Publicado: (2012)

Reply to ‘Malignant pericardial effusion: sclerotherapy or local chemotherapy?’
por: Kunitoh, H, et al.
Publicado: (2009)

The Authors Reply
por: Lee, Taewoo, et al.
Publicado: (2020)

Evaluating new treatments for advanced cancer – reply
por: Ferguson, Jamie
Publicado: (2001)

Reply to: The definition of locally advanced pancreatic cancer
por: Boeck, S, et al.
Publicado: (2010)

Reply: Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Aparicio, T, et al.
Publicado: (2004)

Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Khan, O A, et al.
Publicado: (2012)

Author’s Reply to Professionalism—The Role of Quality Improvement
por: Mueller, Paul S.
Publicado: (2015)

Reply: ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’
por: Gualberto, A, et al.
Publicado: (2011)

Reply to: ‘Advances in imaging of brain abnormalities in neuromuscular disease’
por: Finsterer, Josef
Publicado: (2019)

In Reply: Overall Survival of Resectable Metastatic Colon Cancer Treated With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy in Non-academic Program
por: Hao, Zhonglin, et al.
Publicado: (2023)

Reply to Farrugia: Appropriately specifying the quality of plasma for fractionation
por: Siekmann, Jürgen, et al.
Publicado: (2021)

Author's reply
por: Agati, Salvatore, et al.
Publicado: (2020)

Reply to: “Comment on “Quality of life and unmet needs in patients with chronic liver disease: A mixed-method systematic review””
por: Grønkjær, Lea Ladegaard, et al.
Publicado: (2021)

Reply to comments on “Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei”
por: Hiraide, Sakura, et al.
Publicado: (2021)

Reply: Serum CA-125 and renal impairment in patients undergoing hyperthermic intraperitoneal chemotherapy
por: Chen, Wei-Chun, et al.
Publicado: (2022)

Reply to letter to the editor – ‘resident safety: the perspective of quality improvement’
por: Foster, Paul N.
Publicado: (2014)

Reply: Changes in BMI after treatment of testicular cancer are due to age and hormonal function and not chemotherapy
por: Nord, C, et al.
Publicado: (2003)

Reply: Implications of presymptomatic change in thalamus and caudate in Alzheimer’s disease
por: Ryan, Natalie S., et al.
Publicado: (2013)

REPLY
por: Avasthi, Ajit
Publicado: (2001)

Reply
por: Thoresen, S.
Publicado: (1983)

Reply
por: Forrer, F., et al.
Publicado: (2007)

REPLY
por: Rao, A. Venkoba
Publicado: (2000)

REPLY
por: Malhotra, Savita
Publicado: (2000)

IN REPLY
por: Goswami, Utpal
Publicado: (2003)

Reply :
por: Wig, N.N.
Publicado: (2004)

Reply
por: Andrade, Chittaranjan
Publicado: (2004)

Reply
por: Gada, Manilal
Publicado: (2004)

REPLY
por: Dave, Malay, et al.
Publicado: (2000)

Reply
por: Derasari, Sohan
Publicado: (1989)

Reply
por: Somasundaram, O.
Publicado: (1987)

Reply
por: Abhyankar, Ravi
Publicado: (1986)

Reply
por: Jain, Sanjeev, et al.
Publicado: (1986)

In reply
por: Gorchynski, Julie
Publicado: (2008)

Reply
por: Satija, D.C.
Publicado: (1990)

Reply
por: Mahendru, R.K.
Publicado: (1990)

REPLY
por: Agarwal, A.K.
Publicado: (1999)

REPLY
por: Kumar, P.N. Suresh
Publicado: (1999)

REPLY
por: Chandrasekaran, R.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_b1v4jcchhmbgcjij1p06ic3fpa